查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026921

2034年短腸症候群市場預測－按診斷、治療、藥物類別、通路和地區分類的全球分析

Short Bowel Syndrome Market Forecasts to 2034 - Global Analysis By Diagnosis (Blood Tests, Imaging Procedures, Physical Exam and Other Diagnoses),Treatment, Drug Class, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球短腸症候群市場規模將達到 29 億美元，並在預測期內以 17.9% 的複合年成長率成長，到 2034 年將達到 109 億美元。

一種稱為短腸症候群的複雜疾病，是指部分小腸或大腸發生物理性缺失或功能喪失。因此，短腸症候群患者常出現吸收不良，即脂質、碳水化合物（醣類）、維生素、礦物質、微量元素和水等營養素吸收受損。必需維生素和礦物質的缺乏會導致營養不良、體重無故下降以及其他症狀。

根據 WebMD LLC 於 2021 年發布的數據，每人每年接受腸外營養支持的費用約為 65,000 美元至 320,000 美元。

靜脈輸液需求增加

患有這種疾病的患者越來越需要靜脈輸液來維持正常的尿量和體液水平。鑑於這些患者面臨的困境，業內多家主要企業正致力於解決這項需求。由於髂骨缺失會導致鎂吸收不良和低鎂血症，許多公司正在研發鎂補充劑，以幫助患者保持充足的水分。

危險的副作用

市場面臨的主要挑戰是用於治療短腸症候群的藥物的副作用。 Revestive 和 Gattex 最常見的健康副作用包括頭痛、噁心、嘔吐、感冒和流感。此外，這些藥物也被證實可能引發其他健康問題，例如結腸息肉、膽囊炎、胰管阻塞、可能導致癌症的異常細胞增生以及腸阻塞。

短腸症候群的盛行率

近年來，短腸症候群）的發生率有所上升。接受全靜脈營養的患者人數不斷增加，推動了市場擴張。 SBS的估計發生率為每百萬人4例，但實際發生率更接近每百萬人3例。考慮到接受腸外營養的患者人數，這一數據尚不完全清楚，但該疾病的準確盛行率已被預測。

高昂的醫療費用

治療這種疾病最常見的方法是靜脈營養，但整個療程費用非常昂貴。這種治療既可以在醫院進行，也可以在家中進行。另一方面，在家接受靜脈營養的患者的醫療費用低於在醫院接受治療的患者。此外，治療這種疾病所用藥物的高昂年費用也進一步限制了其市場供應。

新冠疫情的影響：

隨著新冠肺炎患者出現胃腸道疾病的通報增多，短腸症候群）市場的生產者正積極拓展業務，以期獲得更大的利益。然而，SBS的治療通常需要長期腸外營養或器官移植。因此，企業和學術界應攜手合作，推進自體組織工程的研究，以利用患者自身的細胞和組織進行治療。目前，企業正在增加生長激素、腸動力抑制劑和抗胰泌素藥物的產量。

在預測期內，麩醯胺酸產業預計將成為規模最大的產業。

在預測期內，麩醯胺酸板塊預計將成為最大的板塊。麩醯胺酸是一種胺基酸，是腸道內皮細胞的主要能源來源。它支持腸道屏障功能，有助於維持腸粘膜的完整性，甚至可能降低腸道滲透性。麩醯胺酸可能透過促進腸道組織修復和縮短腸道手術後的恢復期來輔助復原。

在預測期內，醫藥產業預計將呈現最高的複合年成長率。

預計在預測期內，醫藥產業將呈現最高的複合年成長率。藥物有助於緩解與該疾病相關的常見症狀，例如腹脹、腹瀉、胃部不適和營養不良。某些藥物可以透過改善營養素和電解質的吸收來彌補腸道功能表面積的減少，有助於預防營養不良及其併發症。

市佔率最大的地區：

預計在預測期內，北美將佔據最大的市場佔有率，這主要受多種因素驅動，例如久坐生活方式的增加、醫療基礎設施的改善以及政府對克隆氏症研究投入的增加。近年來，由於久坐生活方式的盛行、健康飲食時間的減少以及垃圾食物消費量的增加，短腸症候群患者的數量顯著增加。因此，腸道疾病市場持續擴張。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率。該地區市場成長的促進因素包括大型企業的直接進入、對新藥研發的大量投入以及對基於GLP-2治療方法的臨床試驗日益成長的關注。市場擴張的關鍵促進因素包括短腸症候群病例數量的顯著增加（尤其是在新興經濟體）、快速的都市化以及政府對醫療基礎設施投入的增加。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章：全球短腸症候群市場：依藥物類別分類

  • 麩醯胺酸
  • GLP-2
  • 生長激素
  • Zorbtive
  • 質子幫浦阻斷劑
  • 組織胺阻斷劑
  • 升糖素
  • 止瀉藥
  • 其他藥物分類

第6章：全球短腸症候群市場：依分銷管道分類

  • 零售藥房
  • 醫院藥房
  • 線上銷售

第7章：全球短腸症候群市場：依診斷分類

  • 驗血
  • 診斷影像
    • 磁振造影（MRI）
    • 使用造影的X光檢查
    • 電腦斷層掃描（CT）
  • 身體檢查
  • 其他診斷

第8章：全球短腸症候群市場：依治療方式分類

  • 製藥
  • 外科手術
  • 營養療法
    • 經腸營養
    • 腸外營養
  • 移植
  • 其他治療方法

第9章：全球短腸症候群市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • VectivBio AG
  • Takeda Pharmaceutical Company Limited
  • Nutrinia
  • Merck KGaA
  • Ardelyx
  • OxThera Inc
  • Zealand Pharma
  • Nestle Health Science
  • Hanmi Pharm.Co., Ltd
  • Sancilio&Company Inc
  • Meters Biopharma
  • OPKO Health, Inc.
Product Code: SMRC24645

According to Stratistics MRC, the Global Short Bowel Syndrome Market is accounted for $2.9 billion in 2026 and is expected to reach $10.9 billion by 2034 growing at a CAGR of 17.9% during the forecast period. A part of the small or large intestine may physically disappear or cease to function, resulting in the complicated condition known as short bowel syndrome. As a result, malabsorption-the decreased absorption of nutrients such as lipids, carbohydrates (sugars), vitamins, minerals, trace elements, and fluids-occurs often in people with small bowel syndrome. Malnutrition, inadvertent weight loss, and other symptoms might result from the deficiency of vital vitamins and minerals.

According to the data published by WebMD LLC in 2021, the cost of parenteral support per person is around USD 65,000 to USD 320,000 annually.

Market Dynamics:

Driver:

Increased demand of intravenous supplementation of fluids

Patients with this disease are increasingly requiring intravenous fluid supplementation to maintain normal urine flow and hydration levels. Given that these individuals have difficulties, a number of prominent firms in the industry are attempting to address this need. Since the loss of the distal ileum results in malabsorption of magnesium, which causes hypomagnesemia, a number of firms are creating magnesium supplements to aid patients in getting enough water.

Restraint:

Dangerous side effects

The main obstacle facing the market is the adverse effects of medications used to treat short bowel syndrome. The most typical side effects of Revestive or Gattex on health include headaches, nausea, vomiting, colds, and flu. Furthermore, it has been shown that these medications may result in other health issues such colon polyps, gallbladder inflammation, pancreatic obstruction, aberrant cell development that may result in cancer, and intestinal blockage.

Opportunity:

Prevalence of short bowel syndrome

Short bowel syndrome has become more common in recent years. The number of patients receiving complete parenteral nutrition is growing, which has fueled market expansion. The estimated incidence of short bowel syndrome is four cases per million, although actual incidence is closer to three cases per million. Given the amount of patients receiving parenteral nourishment, the disease's precise prevalence is predicted, despite the lack of clarity in this regard.

Threat:

High treatment cost

The most popular therapy for treating this illness is parenteral feeding, which comes with a high expense for the entire course of care. Both in-hospital and at-home environments can perform this treatment. On the other hand, compared to patients getting parenteral nourishment in hospitals, the cost of care for those receiving it at home is lower. Furthermore, the prohibitive yearly expense of the medications used to treat this illness further restricts their commercial acceptance.

Covid-19 Impact:

Manufacturers in the short bowel syndrome market are expanding their income prospects as a result of the results, since individuals with COVID-19 have reported experiencing gastrointestinal issues. On the other hand, long-term parenteral feeding or an organ transplant are necessary for the SBS therapy. Thus, businesses and academics ought to work together to further the field of autologous tissue engineering research, which enables patients to be treated with their own cells or tissues. Businesses are increasing their production of growth hormones, hypomotility drugs and anti-secretin medicines.

The glutamine segment is expected to be the largest during the forecast period

The glutamine segment is expected to be the largest during the forecast period. An amino acid called glutamine is the main energy source for the intestinal lining cells. It supports the operation of the gut barrier, aids in preserving the integrity of the intestinal mucosa, and may even lessen intestinal permeability. By encouraging the repair of the intestinal tissues and shortening the recovery period following intestinal surgery, it may facilitate recuperation.

The medications segment is expected to have the highest CAGR during the forecast period

The medications segment is expected to have the highest CAGR during the forecast period. Drugs can aid in the relief of symptoms including bloating, diarrhea, stomach discomfort, and nutritional deficits that are frequently linked to this illness. Certain drugs can make up for the decreased functional surface area of the gut by improving the absorption of nutrients and electrolytes. This aids in the prevention of malnutrition and its consequences.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the increased sedentary lifestyle, increased healthcare infrastructure, and rising funding from the government on the research of Crohn's disease, among others. The use of short bowel syndrome has expanded significantly in recent years due to the development in sedentary lifestyles, which have left people with less time to focus on eating wholesome foods and more junk food. As a result, the market for intestinal diseases has continued to grow.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The market is growing in this area due to the direct presence of large companies, significant R&D investments in the development of novel medications, and an increasing emphasis on clinical trials for GLP-2-based therapies. The primary reasons propelling the market expansion are the notable increase in short bowel syndrome cases, especially in emerging nations, rapid urbanization, and rising government spending on healthcare infrastructure.

Key players in the market

Some of the key players in Short Bowel Syndrome market include VectivBio AG, Takeda Pharmaceutical Company Limited, Nutrinia, Merck KGaA, Ardelyx, OxThera Inc, Zealand Pharma, Nestle Health Science, Hanmi Pharm.Co., Ltd, Sancilio&Company Inc, Meters Biopharma and OPKO Health, Inc.

Key Developments:

In September 2022, Zealand Pharma A/S announced positive results from a phase 3 trial of Glepaglutide for treatment of short bowel syndrome. Glepaglutide is the potential best-in-class long-acting GLP-2 analog. The candidate has distinct advantages over Teduglutide, including once-weekly dosing and a longer half-life.

In March 2022, VectivBio AG announced a licensing agreement with Asahi Kasei Pharma Corporation to commercialize and develop apraglutide in Japan, which is used to treat SBS.

Diagnoses Covered:

  • Blood Tests
  • Imaging Procedures
  • Physical Exam
  • Other Diagnoses

Treatments Covered:

  • Medications
  • Surgery
  • Nutritional Therapy
  • Transplant
  • Other Treatments

Drug Classes Covered:

  • Glutamine
  • GLP-2
  • Growth Hormone
  • Zorbtive
  • Proton Pump Inhibitors
  • Histamine Blockers
  • Glucagon
  • Anti-Diarrheals
  • Other Drug Classes

Distribution Channels Covered:

  • Medications
  • Surgery
  • Nutritional Therapy
  • Transplant
  • Other Treatments

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Short Bowel Syndrome Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Glutamine
  • 5.3 GLP-2
  • 5.4 Growth Hormone
  • 5.5 Zorbtive
  • 5.6 Proton Pump Inhibitors
  • 5.7 Histamine Blockers
  • 5.8 Glucagon
  • 5.9 Anti-Diarrheals
  • 5.10 Other Drug Classes

6 Global Short Bowel Syndrome Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies
  • 6.3 Hospital Pharmacies
  • 6.4 Online Sales

7 Global Short Bowel Syndrome Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Blood Tests
  • 7.3 Imaging Procedures
    • 7.3.1 Magnetic Resonance Imaging (MRI)
    • 7.3.2 X-ray with a Contrast Material
    • 7.3.2 Computerized Tomography (CT) Scan
  • 7.4 Physical Exam
  • 7.5 Other Diagnoses

8 Global Short Bowel Syndrome Market, By Treatment

  • 8.1 Introduction
  • 8.2 Medications
  • 8.3 Surgery
  • 8.4 Nutritional Therapy
    • 8.4.1 Enteral Nutrition
    • 8.4.2 Parenteral Nutrition
  • 8.5 Transplant
  • 8.6 Other Treatments

9 Global Short Bowel Syndrome Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 VectivBio AG
  • 11.2 Takeda Pharmaceutical Company Limited
  • 11.3 Nutrinia
  • 11.4 Merck KGaA
  • 11.5 Ardelyx
  • 11.6 OxThera Inc
  • 11.7 Zealand Pharma
  • 11.8 Nestle Health Science
  • 11.9 Hanmi Pharm.Co., Ltd
  • 11.10 Sancilio&Company Inc
  • 11.11 Meters Biopharma
  • 11.12 OPKO Health, Inc.

List of Tables

  • Table 1 Global Short Bowel Syndrome Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Short Bowel Syndrome Market Outlook, By Drug Class (2023-2034) ($MN)
  • Table 3 Global Short Bowel Syndrome Market Outlook, By Glutamine (2023-2034) ($MN)
  • Table 4 Global Short Bowel Syndrome Market Outlook, By GLP-2 (2023-2034) ($MN)
  • Table 5 Global Short Bowel Syndrome Market Outlook, By Growth Hormone (2023-2034) ($MN)
  • Table 6 Global Short Bowel Syndrome Market Outlook, By Zorbtive (2023-2034) ($MN)
  • Table 7 Global Short Bowel Syndrome Market Outlook, By Proton Pump Inhibitors (2023-2034) ($MN)
  • Table 8 Global Short Bowel Syndrome Market Outlook, By Histamine Blockers (2023-2034) ($MN)
  • Table 9 Global Short Bowel Syndrome Market Outlook, By Glucagon (2023-2034) ($MN)
  • Table 10 Global Short Bowel Syndrome Market Outlook, By Anti-Diarrheals (2023-2034) ($MN)
  • Table 11 Global Short Bowel Syndrome Market Outlook, By Other Drug Classes (2023-2034) ($MN)
  • Table 12 Global Short Bowel Syndrome Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 13 Global Short Bowel Syndrome Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 14 Global Short Bowel Syndrome Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 15 Global Short Bowel Syndrome Market Outlook, By Online Sales (2023-2034) ($MN)
  • Table 16 Global Short Bowel Syndrome Market Outlook, By Diagnosis (2023-2034) ($MN)
  • Table 17 Global Short Bowel Syndrome Market Outlook, By Blood Tests (2023-2034) ($MN)
  • Table 18 Global Short Bowel Syndrome Market Outlook, By Imaging Procedures (2023-2034) ($MN)
  • Table 19 Global Short Bowel Syndrome Market Outlook, By Magnetic Resonance Imaging (MRI) (2023-2034) ($MN)
  • Table 20 Global Short Bowel Syndrome Market Outlook, By X-ray with a Contrast Material (2023-2034) ($MN)
  • Table 21 Global Short Bowel Syndrome Market Outlook, By Computerized Tomography (CT) Scan (2023-2034) ($MN)
  • Table 22 Global Short Bowel Syndrome Market Outlook, By Physical Exam (2023-2034) ($MN)
  • Table 23 Global Short Bowel Syndrome Market Outlook, By Other Diagnoses (2023-2034) ($MN)
  • Table 24 Global Short Bowel Syndrome Market Outlook, By Treatment (2023-2034) ($MN)
  • Table 25 Global Short Bowel Syndrome Market Outlook, By Medications (2023-2034) ($MN)
  • Table 26 Global Short Bowel Syndrome Market Outlook, By Surgery (2023-2034) ($MN)
  • Table 27 Global Short Bowel Syndrome Market Outlook, By Nutritional Therapy (2023-2034) ($MN)
  • Table 28 Global Short Bowel Syndrome Market Outlook, By Enteral Nutrition (2023-2034) ($MN)
  • Table 29 Global Short Bowel Syndrome Market Outlook, By Parenteral Nutrition (2023-2034) ($MN)
  • Table 30 Global Short Bowel Syndrome Market Outlook, By Transplant (2023-2034) ($MN)
  • Table 31 Global Short Bowel Syndrome Market Outlook, By Other Treatments (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.